{
  "id": 9388478,
  "title": "Rapport Therapeutics at TD Cowen summit: bipolar data loom",
  "url": "https://urgent.news/2026/09/23/rapport-therapeutics-at-td-cowen-summit-bipolar-data-loom",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-23T18:08:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/rapport-therapeutics-at-td-cowen-summit-bipolar-data-loom-93CH-4913720"
  },
  "original_language": "en",
  "account": "On the 23rd of September, 2026, Rapport Therapeutics (RAPP) made a presentation at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. The company primarily focused on its lead drug RAP-219, while acknowledging the need for bipolar mania data to validate the program.\n\nRAPPs, or receptor-associated proteins, form the basis of Rapport's precision neuroscience platform. By leveraging these unique proteins, the company aims to create small molecules with exceptional specificity. This approach also positions Rapport to develop long-acting injectable versions of RAP-219, which could be game-changing for epilepsy treatment.\n\nCurrently, Rapport has strong results in focal onset seizures, with the drug entering Phase III testing. The company expects to submit bipolar mania Phase II data within the next month, making this a crucial near-term catalyst. The company's cash reserves should support its programs until the second half of 2029, providing ample time to advance epilepsy, bipolar mania, and long-acting injectable development.\n\nRAPPs' unique specificity could offer a different tolerability profile from existing bipolar and anti-seizure treatments. Rapport was founded as a collaboration between Third Rock and Johnson & Johnson, with the goal of creating a leading precision neuroscience company. The company's platform aims to achieve uncommon selectivity in neuroscience through receptor-associated proteins.\n\nRAPP-219's potential market opportunities include approximately $2 billion in focal onset seizures and $2 billion in bipolar mania. The bipolar mania market includes around 1.6 million patients in the U.S., while focal onset seizures affect about 1.8 million individuals.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Seaport Therapeutics at TD Cowen summit: pipeline gains momentum",
        "url": "https://urgent.news/2026/09/23/seaport-therapeutics-at-td-cowen-summit-pipeline-gains-momentum",
        "published": "2026-09-23T14:41:20.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}